sur MIG CAPITAL AG
MIG Capital Reports Strategic Investments and Positive 2024 Results
In 2024, MIG Capital, a significant venture capital firm in Germany, successfully navigated a challenging market by investing €41 million in ground-breaking deep tech and life sciences start-ups. Despite Germany's economic downturn, the firm facilitated €232 million in fresh capital to its portfolio companies in collaboration with co-investors.
New additions to MIG's portfolio include HawkCell, a healthcare start-up, GlassPoint in the cleantech sector, and autoimmune biotech, SciRhom. These strategic investments underscore the firm's commitment to innovation in sectors poised for advancement.
In 2025, MIG Capital plans to continue focusing on innovative start-ups and profitable exits. The investment strategy benefits from the solid expertise of professionals like Christina Vogt-Sasse, who joined the team in 2024, bolstering its focus on European deep tech ventures.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de MIG CAPITAL AG